Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
NMPA

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry

SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027

Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027

China's NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting
NMPA

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Show More